Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line

Simple item page
dc.contributor.authorErkmen T.
dc.contributor.authorSerdar B.S.
dc.contributor.authorAteş H.
dc.contributor.authorKorkmaz M.
dc.contributor.authorKoçtürk S.
dc.date.accessioned2024-07-22T08:04:48Z
dc.date.available2024-07-22T08:04:48Z
dc.date.issued2022
dc.description.abstractAcute myeloid leukemia (AML) is the most common form of acute leukemia and has the lowest 5-year survival rates. Current treatment strategies do not meet the expectations also. Therefore, there is a need to improve therapeutic approaches still. Boron, which is a natural trace element in human diet, is gaining attention with its important roles in cellular processes for the development of new anti-cancer drug candidates. For instance, bortezomib, a dipeptidyl boronic acid, has encouraging results in the treatment of multiple myeloma and mantle cell lymphoma. However, severe toxic effects and resistance development are the limitations to its application for AML treatment. Hence, the development of alternative boron-derived anti-AML agents is unmet need. Therefore, we aimed to evaluate anti-leukemic effect of two promising boron compounds, borax pentahydrate (BP) and disodium pentaborate decahydrate (DPD), and comparison of each other in terms of the capacity to trigger apoptosis on acute promyelocytic leukemia cells (HL-60). Cell viability was assessed by MTT assay. Apoptotic effects of the boron compounds on HL-60 cells were evaluated by annexin V/propidium iodide dyes and caspase 3/7 activity assay by flow cytometry. In addition, Bax/Bcl-2 and cleaved PARP levels were detected by western blotting. Although BP showed greater apoptosis-inducing capacity, we observed that both DPD (6 mM) and BP (24 mM) treatment showed anti-leukemic effect by triggering apoptotic pathway through increasing Bax/Bcl-2 ratio for the first time. Our study suggests that BP and DPD are the promising candidates for anti-AML drug development research, which may be confirmed by further wide-spectrum studies. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
dc.identifier.DOI-ID10.1007/s12011-021-02802-2
dc.identifier.issn01634984
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12857
dc.language.isoEnglish
dc.publisherHumana Press Inc.
dc.subjectAdult
dc.subjectApoptosis
dc.subjectbcl-2-Associated X Protein
dc.subjectBorates
dc.subjectHL-60 Cells
dc.subjectHumans
dc.subjectPharmaceutical Preparations
dc.subjectProto-Oncogene Proteins c-bcl-2
dc.subjectantineoplastic agent
dc.subjectborax pentahydrate
dc.subjectcaspase 3
dc.subjectcaspase 7
dc.subjectdisodium pentaborate decahydrate
dc.subjectlipocortin 5
dc.subjectprotein Bax
dc.subjectprotein bcl 2
dc.subjectunclassified drug
dc.subjectborate sodium
dc.subjectboric acid
dc.subjectdrug
dc.subjectprotein Bax
dc.subjectprotein bcl 2
dc.subjectsodium pentaborate
dc.subjectantineoplastic activity
dc.subjectapoptosis
dc.subjectArticle
dc.subjectenzyme activity
dc.subjectflow cytometry
dc.subjectHL-60 cell line
dc.subjecthuman
dc.subjectIC50
dc.subjectMTT assay
dc.subjectWestern blotting
dc.subjectadult
dc.subjectapoptosis
dc.subjectHL-60 cell line
dc.subjectmetabolism
dc.titleBorax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line
dc.typeArticle

Files

Collections

Scopus Koleksiyonu